[go: up one dir, main page]

WO2004012758A1 - Utilisation de tgf beta ig-h3 dans la prevention et le traitement de l'obesite, du diabete et/ou du syndrome metabolique - Google Patents

Utilisation de tgf beta ig-h3 dans la prevention et le traitement de l'obesite, du diabete et/ou du syndrome metabolique Download PDF

Info

Publication number
WO2004012758A1
WO2004012758A1 PCT/EP2003/008244 EP0308244W WO2004012758A1 WO 2004012758 A1 WO2004012758 A1 WO 2004012758A1 EP 0308244 W EP0308244 W EP 0308244W WO 2004012758 A1 WO2004012758 A1 WO 2004012758A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
polypeptide
tgf beta
acid molecule
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/008244
Other languages
English (en)
Inventor
Tri Nguyen
Daria Onichtchouk
Karsten Eulenberg
Günter BRÖNNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Develogen AG
Original Assignee
Develogen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen AG filed Critical Develogen AG
Priority to AU2003251646A priority Critical patent/AU2003251646A1/en
Publication of WO2004012758A1 publication Critical patent/WO2004012758A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Definitions

  • TGF BETA IG-H3 Use of TGF BETA IG-H3 for preventing and treating obesity, diabetes and/or metabolic syndrome
  • This invention relates to the use of a secreted protein referred to as TGF BETA IG-H3, to the use of polynucleotides encoding this protein, and to the use of effectors/modulators thereof in the diagnosis, study, prevention, 0 and treatment of obesity and/or pancreatic diseases such as diabetes mellitus and/or metabolic syndrome and to the use in regeneration of tissues such as pancreatic tissues and Others.
  • human proteins serve as pharmaceutically active compounds. 5 Several classes of human proteins that serve as such active compounds include hormones, cytokines, cell growth factors, and cell differentiation factors. Most proteins that can be used as a pharmaceutically active compound fall within the family of secreted proteins. Secreted proteins are generally produced within cells at rough endoplasmic reticulum, are then 0 exported to the golgi complex, and then move to secretory vesicles or granules, where they are secreted to the exterior of the cell via exocytosis.
  • Examples for commercially used secreted proteins are human insulin, thrombolytic agents, interferons, interleukins, colony stimulating factors, human growth hormone, transforming growth factor beta, tissue 5 plasminogen activator, erythropoietin, ropoeitin, and various other proteins.
  • Receptors of secreted proteins which are membrane-bound proteins, also have potential as therapeutic or diagnostic agents.
  • the pancreas is an essential organ possessing both an exocrine function involved in the delivery of enzymes into the digestive tract and an endocrine function by which various hormones are secreted into the blood stream.
  • the exocrine function is assured by acinar and centroacinar cells that produce various digestive enzymes and intercalated ducts that transport these enzymes in alkaline solution to the duodenum.
  • the functional unit of the endocrine pancreas is the islet of Langerhans.
  • Islets are scattered throughout the exocrine portion of the pancreas and are composed of four cell types: alpha-, beta-, delta- and PP-cells, reviewed for example in Kim & Hebrok, 2001 , Genes & Development 15: 1 1 1 -127.
  • Beta-cells produce, insulin, represent the majority of the endocrine cells and form the core of the islets, while alpha-cells secrete glucagon and are located in the periphery.
  • Delta-cells and PP-cells are less numerous and secrete somatostatin and pancreatic polypeptide, respectively.
  • pancreatic development has been well studied in different species, including chicken, zebrafish, and mice (for a detailed review, see Kim & Hebrock, 2001 , supra).
  • the pancreas develops from distinct dorsal and ventral anlagen.
  • Pancreas development requires specification of the pancreas strom along both anterior-posterior and dorsal-ventral axes.
  • a number of factors which are critical for proper pancreatic development have been identified (see Kim & Hebrok, 2001 , Genes & Development 15:1 1 1 -127; 1 : Wilson, Scheel & German Mech Dev. 120:65-80).
  • pancreatic cell fates as well as the morphogenesis of pancreatic structures, for example FGF signaling, activin signaling, the Hedgehog pathway, notch signaling, vascular epithelial growth factor (VEGF) signaling, NCAM-mediated signaling, and the transforming growth factor (TGF)-beta signaling pathway.
  • FGF signaling for example FGF signaling, activin signaling, the Hedgehog pathway, notch signaling, vascular epithelial growth factor (VEGF) signaling, NCAM-mediated signaling, and the transforming growth factor (TGF)-beta signaling pathway.
  • VEGF vascular epithelial growth factor
  • TGF transforming growth factor
  • pancreatic islets of Langerhans originate from differentiating duct cells or othercells with epithelial morphology (Bonner-Weir & Sharma A, J, J Pathol. 197:519-26; Gu G et al., Mech Dev. 2003 Jan;120(1 ):35-43).
  • Pancreatic beta-cells secrete insulin which is stimulated by high blood glucose levels. Insulin amongst other hormones plays a key role in the regulation of the fuel metabolism. Insulin leads to the storage of glycogen and triglycerides and to the synthesis of proteins. The entry of glucose into muscles and adipose cells is stimulated by insulin. In patients who suffer from diabetes mellitus the amount of insulin produced by the pancreatic islet cells is too low, resulting in elevated blood glucose levels (hyperglycemia). In diabetes type 1 beta cells are lost due to autoimmune destruction. In type 2 diabetic patients, liver and muscle cells loose their ability to respond to normal blood insulin levels (insulin resistance).
  • pancreatic islets In type 1 diabetics, the lifespan of pancreatic islets is dramatically shortened due to autoimmune destruction. Treatments have been devised which modulate the immune system and may be able to stop or strongly reduce islet destruction (Raz I. et al., Lancet. 2001 Nov 24;358(9295):1749-53; Chatenoud L. et al., Nat Rev Immunol. 2003 Feb;3(2): 123-32). However, due to the relatively slow regeneration of human beta cells such treatments could only be fully successful at improving the diabetic condition if they are combined with an agent which can stimulate beta cell regeneration.
  • Diabetes is a very disabling disease, because medications do not control blood sugar levels well enough to prevent swinging between high and low blood sugar levels.
  • Patients with diabetes are at risk for major complications, including diabetic ketoacidosis, end-stage renal disease, diabetic retinopathy and amputation.
  • diabetes There are also a host of related conditions, such as metabolic syndrome, obesity, hypertension, heart disease, peripheral vascular disease, and infections, for which persons with diabetes are at substantially increased risk.
  • the treatment of these complications contributes to a considerable degree to the enormous cost which is imposed by diabetes on health care systems world wide.
  • Obesity is one of the most prevalent metabolic disorders in the world. It is still a poorly understood human disease that becomes as a major health problem more and more relevant for western society. Obesity is defined as a body weight more than 20% in excess of the ideal body weight, frequently resulting in a significant impairment of health. Obesity may be measured by body mass index, an indicator of adiposity or fatness. Further parameters for defining obesity are waist circumferences, skinfold thickness and bioimpedance (see, inter alia, Kopelman (1999), loc. cit.). It is associated with an increased risk for cardiovascular disease, hypertension, diabetes mellitus type 2, hyperlipidaemia and an increased mortality rate.
  • Obesity is influenced by genetic, metabolic, biochemical, psychological, and behavioral factors and can be caused by different reasons such as non-insulin dependent diabetes, increase in triglycerides, increase in carbohydrate bound energy and low energy expenditure. As such, it is a complex disorder that must be addressed on several fronts to achieve lasting positive clinical outcome. Since obesity is not to be considered as a single disorder but as a heterogeneous group of conditions with (potential) multiple causes, it is also characterized by elevated fasting plasma insulin and an exaggerated insulin response to oral glucose intake (Koltermann J., (1980) Clin. Invest 65, 1272-1284). A clear involvement of obesity in type 2 diabetes mellitus can be confirmed (Kopelman P.G., (2000) Nature 404, 635-643).
  • the metabolic syndrome often precedes the development of type II diabetes and cardiovascular disease (McCook, 2002, JAMA 288:2709-2716).
  • the control of blood lipid levels and blood glucose levels is the essential for the treatment of the metabolic syndrome (see, for example, Santomauro A. T. et al., (1999) Diabetes, 48(9):1836-1841 ).
  • Secreted proteins are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize novel functions for secreted proteins.
  • the present invention advances the state of the art by providing previously unknown functions for a human secreted protein. Accordingly, the present invention relates to a secreted protein with novel functions in the human metabolism and regeneration processes.
  • the present invention discloses the use of specific genes and proteins encoded thereby and effectors/modulators thereof involved in the regulation of metabolism, especially in the disorders of the pancreas (e.g.
  • diabetes mellitus such as insulin-dependent diabetes mellitus and/or non-insulin dependent diabetes mellitus
  • metabolic syndrome obesity, and related disorders such as for example but not limited to coronary heart disease, eating disorder, cachexia, hypertension, hypercholesterolemia (dyslipidemia), and/or gallstones.
  • this invention particularly describes a secreted protein which is specifically expressed in pancreatic tissues early in the development.
  • the invention relates to the use of this gene, its homologues and encoded proteins and effectors/modulators thereof in the diagnosis, prevention and/or treatment of pancreatic dysfunctions, such as diabetes, and other related diseases such as obesity and/or metabolic syndrome.
  • These compounds are especially useful in regeneration processes, such as regeneration of the pancreas cells or tissues, e.g.
  • cells having exocrinous functions such as acinar cells, centroacinar cells and/or ductal cells, and/or cells having endocrinous functions, particularly cells in Langerhans islets such as alpha-, beta-, delta- and/or PP-cells, more particularly beta-cells.
  • the compounds are especially useful in the modulation, e.g. stimulation of pancreatic development.
  • the present invention relates to TGF BETA IG-H3 polynucleotides encoding polypeptides with novel functions in mammalian metabolism, including body-weight regulation, energy homeostasis, obesity, and pancreatic diseases (diabetes), fragments of said polynucleotides, polypeptides encoded by said polynucleotides or fragments thereof.
  • the invention also relates to vectors, host cells, and recombinant methods for producing the polypeptides and polynucleotides of the invention.
  • the invention also relates to effectors/modulators of TGF BETA IG-H3 polynucleotides and/or polypeptides, e.g. antibodies, biologically active nucleic acids, such as antisense molecules, RNAi molecules or ribozymes, aptamers, peptides or low-molecular weight organic compounds recognizing said polynucleotides or polypeptides.
  • model organisms such as the fly Drosophila melanogaster
  • the ability to manipulate and screen the genomes of model organisms provides a powerful tool to analyze biological and biochemical processes that have direct relevance to more complex vertebrate organisms due to significant evolutionary conservation of genes, cellular processes, and pathways (see, for example, Adams M.
  • a forward genetic screen is performed in fly displaying a mutant phenotype due to misexpression of a known gene (see, Johnston, Nat Rev Genet 3: 176-188 (2002); Rorth, (1996) Proc Natl Acad Sci USA 93: 12418-12422).
  • this invention we have used a genetic screen to identify mutations of Saposin-related homologous genes that cause changes in the body weight, which are reflected by a significant change of triglyceride levels. Additionally glycogen levels are analysed.
  • One resource for screening was a Drosophila melanogaster stock collection of EP-lines.
  • the P-vector of this collection has Gal4-UAS-binding sites fused to a basal promoter that can transcribe adjacent genomic Drosophila sequences upon binding of Gal4 to UAS-sites (Brand & Perrimon (1993) Development 1 18:401 -415; Rorth, supra).
  • This enables the EP-line collection for overexpression of endogenous flanking gene sequences.
  • integration of the EP-element into the gene is likely to cause a reduction of gene activity, and allows determining its function by evaluating the loss-of-function phenotype.
  • the content of triglycerides and glycogen of a pool of flies with the same genotype was analyzed after feeding for six days using a triglyceride and a glycogen assay.
  • Male flies homozygous for the integration of vectors for Drosophila lines HD-EP(3)36824 were analyzed in assays measuring the triglyceride/glycogen contents of these flies (illustrated in more detail in the Examples section).
  • the results of the triglyceride/glycogen content analysis are shown in Figure 1 .
  • Genomic DNA sequences were isolated that are localized directly adjacent to the EP vector (herein HD-EP(3)35618 and HD-EP(3)2580) integration. Using those isolated genomic sequences public databases like Berkeley Drosophila Genome Project (GadFly; see also FlyBase (1999) Nucleic Acids Research 27:85-88) were screened thereby identifying the integration site of the vectors, and the corresponding gene, described in more detail in the Examples section. The molecular organization of the gene is shown in Figure 2. The so identified Drosophila gene called Fasciclin 1 encodes for a cell adhesion molecule involved in neuronal cell adhesion, which is a component of the plasma membrane.
  • Fasciclin 1 is a lipid-linked cell-surface glycoprotein that can act as a homophilic adhesion molecule in tissue culture cells. It is involved in growth cone guidance in the embryonic insect nervous system. Fasciclin 1 may define a new structural motif used to mediate adhesive interactions between cell surfaces (Wang W. C. et al., (1993) J Biol Chem 268(2):1448-1455). The Drosophila genes and proteins encoded thereby with functions in the regulation of triglyceride metabolism were further analysed in publicly available sequence databases (see Eamples for more detail) and mammalian homologs were identified (see Figure 3). We found that Fasciclin 1 is homologous to human transforming growth factor, beta-induced, 68 kD (referred to as TGF BETA IG-H3 in this invention) and to human osteoblast specific factor 2.
  • Fat cells surrounding the internal organs play an especially important role in the pathophysiology of obesity e.g. Gasteyger C and Tremblay A., J Endocrinol Invest. 2002 Nov;25(10):876-83.
  • adipocytes are mesodermally derived cells, it is likely that they originate from the mesenchymal cells located around the organ primordial during embryonic development.
  • the pancreatic bud which was used as starting material in the secreted factor screen which lead to the identification of TGF BETA IG-H3 most likely contained both pancreatic precursor cells and precursors of visceral adipocytes (or cells controlling their differentiation).
  • TGF BETA IG-H3 was discussed as cell surface recognition protein, having a suggested role in cell-cell communication and transmission of intracellular signals involved in negative growth control (see Skonier et al., 1994, DNA Cell Biol 13(6):571 -84).
  • TGF BETA IG-H3 was also found as an extracellular protein in the corneal epithelium (Escribano et al., 1994, J Cell Physiol 160(3):51 1 -21), and excessive amounts were found in human corneas with granular dystrophy (GCD), suggesting a role in the characteristic corneal accumulations in this eye disease (Klintworth et al., 1998, Am J Pathol 152(3):743-8). TGF BETA IG-H3 was also found in normal human skin, especially in the papillary dermis.
  • TGF BETA IG-H3 supported attachment and spreading of dermal fibroblasts, suggesting that it may function as an extracellular attachment protein in skin (see LeBaron et al., 1995, J Invest Dermatol 104(5):844-9). Also, the expression of TGF BETA IG-H3 in diseased human arterial tissue was described, suggesting a role in atherogenesis and restenosis (O'Brien et al., 1996, Arterioscler Thromb Vase Biol 16(4):576-84). Also, a renal expression of TGF BETA IG-H3 was described in normal and diabetic rats.
  • TGF-beta plays a pathogenetic role in kidney disease and suggest that TGF BETA IG-H3 may be a useful index of TGF-beta 1 bioactivity in the kidney (see, Gilbert et al., 1998, Kidney Int 54(4) -.1052-62).
  • TGF BETA IG-H3 in metabolic disorders such as obesity, diabetes, or metabolic syndrome or describes a function of TGF BETA IG-H3 in regeneration processes, for example, in the regeneration of pancreatic cells (e.g. beta-cells).
  • TGF BETA IG-H3 homologous proteins and nucleic acid molecules coding therefore are obtainable from vertebrate species.
  • Particularly preferred are nucleic acids encoding the human TGF BETA IG-H3 protein and variants thereof.
  • the invention particularly relates to a nucleic acid molecule encoding a polypeptide contributing to regulating the energy homeostasis and the mammalian metabolism, wherein said nucleic acid molecule comprises
  • nucleic acid molecule of (a) to (d) by mutation a sequence which differs from the nucleic acid molecule of (a) to (d) by mutation and wherein said mutation causes an alteration, deletion, duplication and/or premature stop in the encoded polypeptide
  • TGF BETA IG-H3 The function of the mammalian TGF BETA IG-H3 in mammalian metabolism was validated by analyzing the expression of the transcripts in different tissues and by analyzing the role in adipocyte differentiation. Expression profiling studies (see Examples for more detail) confirm the particular relevance of TGF BETA IG-H3 as regulator of energy metabolism in mammals. Taqman analysis revealed that TGF BETA IG-H3 is expressed in several mammalian tissues, with highest expression levels in spleen, lung, small intestine, testis, liver, bone marrow, and muscle (see FIGURE 4A).
  • TGF BETA IG-H3 is highly expressed in metabolic active tissue such as white adipose tissue (WAT) and brown adipose tissue (BAT) as depicted in FIGURE 4A.
  • WAT white adipose tissue
  • BAT brown adipose tissue
  • FIGURE 4A One important task of BAT is to generate heat and maintain body temperature homeostasis in newborn.
  • an expression of TGF BETA IG-H3 protein in adipose tissues is confirming a role in the regulation of metabolism, particularly energy homeostasis and thermogenesis.
  • mice carrying mutations in the leptin pathway for example, ob/ob (leptin) or db (leptin receptor/ligand) mice
  • TGF BETA IG-H3 mice carrying mutations in the leptin pathway
  • TGF BETA IG-H3 is strongly upregulated in metabolic active tissue (BAT, WAT) in genetically induced obese mice (ob/ob) compared to fasted mice (see FIGURE 4B).
  • TGF BETA IG-H3 mRNA was also examined in susceptible wild type mice (for example, C57BI/6) that show symptoms of diabetes, lipid accumulation, and high plasma lipid levels, if fed a high fat diet. In those mice, the expression of TGF BETA IG-H3 is significantly upregulated in several tissues, including liver, testis, heart, WAT, and BAT supporting th at TGF BETA IG-H3 is involved in the regulation of mammalian metabolism (see FIGURE 4C).
  • Microarrays are analytical tools routinely used in bioanalysis.
  • a microarray has molecules distributed over, and stably associated with, the surface of a solid support.
  • the term "microarray” refers to an arrangement of a plurality of polynucleotides, polypeptides, antibodies, or other chemical compounds on a substrate.
  • Microarrays of polypeptides, polynucleotides, and/or antibodies have been developed and find use in a variety of applications, such as monitoring gene expression, drug discovery, gene sequencing, gene mapping, bacterial identification, and combinatorial chemistry.
  • One area in particular in which microarrays find use is in gene expression analysis (see Example 4).
  • array technology can be used to explore the expression of a single polymorphic gene or the expression profile of a large number of related or unrelated genes.
  • arrays are employed to detect the expression of a specific gene or its variants.
  • arrays provide a platform for identifying genes that are tissue specific, are affected by a substance being tested in a toxicology assay, are part of a signaling cascade, carry out housekeeping functions, or are specifically related to a particular genetic predisposition, condition, disease, or disorder.
  • Microarrays may be prepared, used, and analyzed using methods known in the art (see for example, Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796- Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251 1 16; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:21502155; Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662).
  • Various types of microarrays are well known and thoroughly described in Schena, M., ed. (1 999; DNA Microarrays: A Practical Approach, Oxford University Press, London).
  • Oligonucleotides or longer fragments derived from any of the polynucleotides described herein may be used as elements on a microarray.
  • the microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below.
  • the microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.
  • TGF BETA IG-H3 shows differential expression in human primary adipocytes. A strong downregulation is observed concerning the expression of TGF BETA IG-H3 is during the human adipocyte differentiation (see FIGURE 5 A and B) .
  • the TGF BETA IG-H3 protein in preadipocyctes has the potential to inhibit adipose differentiation at a very early stage. Therefore, the TGF BETA IG-H3 protein might play an essential role in adipogenesis.
  • the results are suggesting a role of TGF BETA IG-H3 in the regulation in human metabolism, for example, as effector/modulator (for example, inhibitor) of adipogenesis.
  • TGF BETA IG-H3 is a strong candidate for the manufacture of a pharmaceutical composition and a medicament for the treatment of conditions related to human metabolism, such as obesity, diabetes, and/or metabolic syndrome.
  • the invention also encompasses the novel use of polynucleotides that encode TGF BETA IG-H3. Accordingly, any nucleic acid sequence, which encodes the amino acid sequences of TGF BETA IG-H3, can be used to generate recombinant molecules that express TGF BETA IG-H3.
  • nucleotide sequences encoding the proteins may be produced.
  • the invention contemplates each and every possible variation of nucleotide sequence that o can be made by selecting combinations based on possible codon choices.
  • polynucleotide sequences that are capable of hybridizing to the claimed nucleotide sequences, and in particular, those of the polynucleotide encoding the proteins of the 5 invention, under various conditions of stringency.
  • Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex or probe, as taught in Wahl & Berger (1987: Methods Enzymol. 152:399-407) and Kimmel (1987; Methods Enzymol. 152:507-51 1 ), and may be used at a defined stringency.
  • hybridization under 0 stringent conditions means that after washing for 1 h with 1 x SSC and 0.1 % SDS at 50°C, preferably at 55°C, more preferably at 62°C and most preferably at 65 °C, particularly for 1 h in 0.2 x SSC and 0.1 % SDS at 50°C, preferably at 55°C, more preferably at 62°C and most preferably at 65 °C, a positive hybridization signal is observed.
  • Altered nucleic acid 5 sequences encoding the proteins which are encompassed by the invention include deletions, insertions or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent protein.
  • the encoded proteins may also contain deletions, insertions or substitutions of amino acid residues, which produce a silent change and result in functionally equivalent proteins. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of the protein is retained.
  • the invention relates to peptide fragments of the proteins or derivatives thereof such as cyclic peptides, retro-inverso peptides or peptide mimetics having a length of at least 4, preferably at least 6 and up to 50 amino acids.
  • an 'allele' or 'allelic sequence' is an alternative form of the gene, which may result from at least one mutation in the nucleic acid sequence. Alleles may result in altered mRNAs or polypeptides whose structures or function may or may not be altered. Any given gene may have none, one or many allelic forms. Common mutational changes, which give rise to alleles, are generally ascribed to natural deletions, additions or substitutions of nucleotides. Each of these types of changes may occur alone or in combination with the others, one or more times in a given sequence.
  • TGF BETA IG-H3 and homologous proteins may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements.
  • nucleotide sequences encoding the proteins or functional equivalents may be inserted into appropriate expression vectors, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.
  • appropriate expression vectors i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.
  • Methods which are well known to those skilled in the art, may be used to construct expression vectors containing sequences encoding the proteins and the appropriate transcriptional and translational control elements.
  • Regulatory elements include for example a promoter, an initiation codon, a stop codon, a mRNA stability regulatory element, and a polyadenylation signal.
  • a polynucleotide can be assured by (i) constitutive promoters such as the Cytomegalovirus (CMV) promoter/enhancer region, (ii) tissue specific promoters such as the insulin promoter (see, Soria et al., 2000, Diabetes 49:157), SOX2 gene promotor (see Li et al., (1998) Curr. Biol. 8:971 -974), Msi-1 promotor (see Sakakibara et al., (1997) J. Neuroscience 17:8300-8312), alpha-cardia myosin heavy chain promotor or human atrial natriuretic factor promotor (Klug et al., (1996) J. clin.
  • constitutive promoters such as the Cytomegalovirus (CMV) promoter/enhancer region
  • tissue specific promoters such as the insulin promoter (see, Soria et al., 2000, Diabetes 49:157), SOX2 gene promotor (see Li et al.
  • Expression vectors can also contain a selection agent or marker gene that confers antibiotic resistance such as the neomycin, hygromycin or puromycin resistance genes.
  • selection agent or marker gene confers antibiotic resistance such as the neomycin, hygromycin or puromycin resistance genes.
  • natural, modified or recombinant nucleic acid sequences encoding TGF BETA IG-H3 may be ligated to a heterologous sequence to encode a fusion protein.
  • a variety of expression vector/host systems may be utilized to contain and express sequences encoding the proteins or fusion proteins.
  • micro-organisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus, adenovirus, adeno-associated virus, lentiverus, retrovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or PBR322 plasmids); or animal cell systems.
  • virus expression vectors e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV
  • bacterial expression vectors e.g., Ti or PBR322 plasmids
  • TGF BETA IG-H3 polynucleotides in a sample can be detected by DNA-DNA or DNA-RNA hybridization and/or amplification using probes or portions or fragments of said polynucleotides.
  • Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the sequences specific for the gene to detect transformants containing DNA or RNA encoding the corresponding protein.
  • 'oligonucleotides' or 'oligomers' refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides, which can be used as a probe or amplimer.
  • Means for producing labeled hybridization or PCR probes for detecting polynucleotide sequences include oligo-labeling, nick translation, end-labeling of RNA probes, PCR amplification using a labeled nucleotide, or enzymatic synthesis. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, Mich.); Promega (Madison Wis.); and U.S. Biochemical Corp., (Cleveland, Ohio).
  • TGF BETA IG-H3 The presence of TGF BETA IG-H3 in a sample can be determined by immunological methods or activity measurement.
  • a variety of protocols for detecting and measuring the expression of proteins, using either polyclonal or monoclonal antibodies specific for the protein or reagents for determining protein activity are known in the art. Examples include enzyme-linked immunosorbentassay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS).
  • ELISA enzyme-linked immunosorbentassay
  • RIA radioimmunoassay
  • FACS fluorescence activated cell sorting
  • a two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on the protein is preferred, but a competitive binding assay may be employed.
  • Suitable reporter molecules or labels include radionuclides, enzymes, fluorescent, chemiluminescent or chromogenic agents as well as substrates, co-factors, inhibitors, magnetic particles, and the like.
  • the nucleic acids encoding TGF BETA IG-H3 can be used to generate transgenic animal or site specific gene modifications in cell lines.
  • Transgenic animals may be made through homologous recombination, where the normal locus of the genes encoding the proteins of the invention is altered.
  • a nucleic acid construct is randomly integrated into the genome.
  • Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like.
  • the modified cells or animal are useful in the study of the function and regulation of the proteins of the invention. For example, a series of small deletions and/or substitutions may be made in the genes that encode the proteins of the invention to determine the role of particular domains of the protein, functions in pancreatic differentiation, etc.
  • Specific constructs of interest include anti-sense molecules, which will block the expression of the proteins of the invention, or expression of dominant negative mutations.
  • a detectable marker such as for example lac-Z, may be introduced in the locus of the genes of the invention, where upregulation of expression of the genes of the invention will result in an easily detected change in phenotype.
  • One may also provide for expression of the genes of the invention or variants thereof in cells or tissues where it is not normally expressed or at abnormal times of development.
  • by providing expression of the proteins of the invention in cells in which they are not normally produced one can induce changes in cell behavior.
  • DNA constructs for homologous recombination will comprise at least portions of the genes of the invention with the desired genetic modification, and will include regions of homology to the target locus.
  • DNA constructs for random integration need not include regions of homology to mediate recombination. Conveniently, markers for positive and/or negative selection are included.
  • Methods for generating cells having targeted gene modifications through homologous recombination are known in the art.
  • ES non-humanembryonic stem
  • an ES cell line may be employed, or embryonic cells may be obtained freshly from a host, e.g. mouse, rat, guinea pig etc. Such cells are grown on an appropriate fibroblast-feeder layer or grown in presence of leukemia inhibiting factor (LIF).
  • LIF leukemia inhibiting factor
  • non-human ES or embryonic cells or somatic pluripotent stem cells When non-human ES or embryonic cells or somatic pluripotent stem cells have been transformed, they may be used to produce transgenic animals.
  • the cells are plated onto a feeder layer in an appropriate medium.
  • Cells containing the construct may be detected by employing a selective medium. After sufficient time for colonies to grow, they are picked and analyzed for the occurrence of homologous recombination or integration of the construct. Those colonies that are positive may then be used for embryo transfection and blastocyst injection.
  • Blastocysts are obtained from 4 to 6 week old superovulated females.
  • ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are returned to each uterine horn of pseudopregnant females. Females are then allowed to go to term and the resulting offspring screened for the construct.
  • chimeric progeny can be readily detected. The chimeric animals are screened for the presence of the modified gene and males and females having the modification are mated to produce homozygous progeny.
  • tissues or organs can be maintained as allogenic or congenic grafts or transplants, or in vitro culture.
  • the transgenic animals may be any non-human mammal, such as laboratory animal, domestic animals, etc.
  • the transgenic animals may be used in functional studies, drug screening, etc.
  • TGF BETA IG-H3 nucleic acids and proteins and effector/modulator molecules thereof are useful in diagnostic and therapeutic applications implicated, for example, but not limited to, metabolic syndrome, obesity, diabetes mellitus such as insulin dependent diabetes mellitus and/or non-insulin dependent diabetes mellitus, eating disorder, cachexia, hypertension, coronary heart disease, hypercholesterolemia (dyslipidemia), and/or gallstones.
  • nucleic acids and proteins of the invention are, for example but not limited to, the following: (i) tissue regeneration in vitro and in vivo (regeneration for all these tissues and cell types composing these tissues and cell types derived from these tissues), (ii) protein therapy, (iii) small molecule drug target, (iv) antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (v) diagnostic and/or prognostic marker, (vi) gene therapy (gene delivery/gene ablation), and (vii) research tools.
  • compositions of the present invention will have efficacy for treatment of patients suffering from, for example, pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome as described above.
  • pancreatic diseases e.g. diabetes
  • TGF BETA IG-H3 nucleic acids and proteins and/or effectors / modulators e.g. antagonists
  • the composition will then at least partially restore normal pancreatic function.
  • these cells are beta cells of the islets which will contribute to the improvement of a diabetic state.
  • an increase in beta cell mass can be achieved. This effect upon the body reverses the condition of diabetes partially or completely.
  • the dosage administered is reduced in strength. In at least some cases further administration can be discontinued entirely and the subject continues to produce a normal amount of insulin without further treatment. The subject is thereby not only treated but cured entirely of a diabetic condition.
  • even moderate improvements in beta cell mass can lead to a reduced requirement for exogenous insulin, improved glycemic control and a subsequent reduction in diabetic complications.
  • other cells of the pancreas can be regenerated in vivo or in vitro to cure a certain condition.
  • compositions of the present invention will also have efficacy for treatment of patients with other pancreatic diseases such pancreatic cancer, dysplasia, or pancreatitis.
  • TGF BETA IG-H3 nucleic acids and proteins and effectors/modulators thereof are useful in diagnostic and therapeutic applications implicated in various applications as described below.
  • cDNAs encoding TGF BETA IG-H3 may be useful in gene therapy, and TGF BETA IG-H3 proteins may be useful when administered to a subject in need thereof.
  • the compositions of the present invention will have efficacy for treatment of patients suffering from, for example, pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome as described above.
  • nucleic acids of the invention or fragments thereof may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acids or the proteins are to be assessed.
  • Further antibodies that bind immunospecifically to the novel substances of the invention may be used in therapeutic or diagnostic methods.
  • antibodies which are specific for TGF BETA IG-H3, may be used directly as an effector/modulator, e.g. an antagonist or an agonist, indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express the protein.
  • the antibodies may be generated using methods that are well known in the art.
  • Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric single chain, Fab fragments, and fragments produced by a Fab expression library.
  • Neutralising antibodies i.e., those which inhibit dimer formation are especially preferred for therapeutic use.
  • various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with the protein or any fragment or oligopeptide thereof which has immunogenic properties.
  • various adjuvants may be used to increase immunological response. It is preferred that the peptides, fragments or oligopeptides used to induce antibodies to the protein have an amino acid sequence consisting of at least five amino acids, and more preferably at least 10 amino acids.
  • Monoclonal antibodies to the proteins may be prepared using any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (K ⁇ hler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81 :31 -42; Cote, R. J. et al. Proc. Natl. Acad. Sci. 80:2026-2030; Cole, S. P. et al. (1984) Mol. Cell Biol. 62: 109-120).
  • Antibodies with related specificity, but of distinct idiotypic composition may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton, D. R. (1991 ) Proc. Natl. Acad. Sci. 88:1 1 120-1 1 123). Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86:3833-3837; Winter, G. et al. (1991 ) Nature 349:293-299).
  • Antibody fragments which contain specific binding sites for the proteins may also be generated.
  • fragments include, but are not limited to, the F(ab') 2 fragments which can be produced by Pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of F(ab') 2 fragments.
  • Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse, W. D. et al. (1989) Science 254: 1275-1281 ).
  • Various immunoassays may be used for screening to identify antibodies having the desired specificity.
  • the polynucleotides or fragments thereof or nucleic acid effector/modulator molecules such as antisense molecules, aptamers, RNAi molecules or ribozymes may be used for therapeutic purposes.
  • aptamers i.e. nucleic acid molecules, which are capable of binding to TGF BETA IG-H3 and modulating its activity, may be generated by a screening and selection procedure involving the use of combinatorial nucleic acid libraries, e.g. as described in WO 91/19813.
  • antisense molecules may be used in situations in which it would be desirable to block the transcription of the mRNA.
  • cells may be transformed with sequences complementary to polynucleotides encoding TGF BETA IG-H3 and homologous proteins.
  • antisense molecules may be used to modulate/effect protein activity or to achieve regulation of gene function.
  • sense or antisense oligomers or larger fragments can be designed from various locations along the coding or control regions of sequences encoding the proteins.
  • Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses or from various bacterial plasmids may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods, which are well known to those skilled in the art, can be used to construct recombinant vectors, which will express antisense molecules complementary to the polynucleotides of the genes encoding TGF BETA IG-H3. These techniques are described both in Sambrook et al. (supra) and in Ausubel et al. (supra).
  • Genes encoding TGF BETA IG-H3 can be turned off by transforming a cell or tissue with expression vectors, which express high levels of polynucleotides that encode TGF BETA IG-H3 or fragments thereof. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.
  • antisense molecules e.g. DNA, RNA or nucleic acid analogues such as PNA
  • PNA nucleic acid analogues
  • Oligonucleotides derived from the transcription initiation site e.g., between positions -10 and + 10 from the start site, are preferred.
  • inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it cause inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors or regulatory molecules.
  • the antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.
  • Ribozymes enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA.
  • the mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples, which may be used, include engineered hammerhead motif ribozyme molecules that can be specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding TGF BETA IG-H3.
  • Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC.
  • RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable.
  • the suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.
  • Nucleic acid effector/modulator molecules e.g. antisense molecules and ribozymes may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis.
  • RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences. Such DNA sequences may be incorporated into a variety of vectors with suitable RNA polymerase promoters such as T7 or SP6.
  • these cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells or tissues. RNA molecules may be modified to increase intracellular stability and half-life.
  • flanking sequences at the 5' and/or 3' ends of the molecule or modifications in the nucleobase, sugar and/or phosphate moieties, e.g. the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule.
  • vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection and by liposome injections may be achieved using methods, which are well known in the art. Any of the therapeutic methods described above may be applied to any suitable subject including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.
  • An additional embodiment of the invention relates to the administration of a pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above.
  • Such pharmaceutical compositions may consist of TGF BETA IG-H3 nucleic acids and the proteins and homologous nucleic acids or proteins, antibodies to TGF BETA IG-H3, mimetics, agonists, antagonists or inhibitors of TGF BETA IG-H3 or nucleic acids.
  • the compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water.
  • compositions may be administered to a patient alone or in combination with other agents, drugs or hormones.
  • the pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual or rectal means.
  • these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations, which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.).
  • compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose.
  • the determination of an effective dose is well within the capability of those skilled in the art.
  • the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of preadipocyte cell lines or in animal models, usually mice, rabbits, dogs or pigs.
  • the animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • a therapeutically effective dose refers to that amount of active ingredient, for example the TGF BETA IG-H3 nucleic acids or proteins or fragments thereof or antibodies, which is sufficient for treating a specific condition.
  • Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population).
  • the dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50.
  • Pharmaceutical compositions, which exhibit large therapeutic indices, are preferred.
  • the data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use.
  • the dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage from employed. sensitivity of the patient, and the route of administration.
  • Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors, which may be taken into account, include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy.
  • Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week or once every two weeks depending on half-life and clearance rate of the particular formulation. Normal dosage amounts may vary from 0.1 to 100,000 microg, up to a total dose of about 1 g, depending upon the route of administration.
  • antibodies which specifically bind to the proteins may be used for the diagnosis of conditions or diseases characterized by or associated with over- or underexpression of TGF BETA IG-H3 or in assays to monitor patients being treated with TGF BETA IG-H3, or effectors/modulators thereof, e.g. agonists, antagonists, or inhibitors. Diagnostic assays include methods which utilize the antibody and a label to detect the protein in human body fluids or extracts of cells or tissues.
  • the antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule.
  • reporter molecules which are known in the art may be used several of which are described above.
  • a variety of protocols including ELISA, RIA, and FACS for measuring proteins are known in the art and provide a basis for diagnosing altered or abnormal levels of gene expression.
  • Normal or standard values for gene expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibodies to the protein under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, but preferably by photometric means. Quantities of protein expressed in control and disease, samples e.g. from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.
  • the polynucleotides specific for the TGF BETA IG-H3 proteins and homologous proteins may be used for diagnostic purposes.
  • the polynucleotides, which may be used include oligonucleotide sequences, antisense RNA and DNA molecules, and PNAs.
  • the polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which gene expression may be correlated with disease.
  • the diagnostic assay may be used to distinguish between absence, presence, and excess gene expression, and to monitor regulation of protein levels during therapeutic intervention.
  • hybridization with probes which are capable of detecting polynucleotide sequences may be used to identify nucleic acid sequences which encode the respective protein.
  • the hybridization probes of the subject invention may be DNA or RNA and are preferably derived from the nucleotide sequence of the polynucleotide encoding the proteins of the invention or from a genomic sequence including promoter, enhancer elements, and introns of the naturally occurring gene.
  • Hybridization probes may be labeled by a variety of reporter groups, for example, radionuclides such as 32 P or 35 S or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.
  • reporter groups for example, radionuclides such as 32 P or 35 S or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.
  • Polynucleotide sequences specific for TGF BETA IG-H3 proteins and homologous nucleic acids may be used for the diagnosis of conditions or diseases, which are associated with the expression of the proteins. Examples of such diseases include the obesity, diabetes, metabolic syndrome, and/or others). Polynucleotide sequences specific for the TGF BETA IG-H3 proteins and homologous proteins may also be used to monitor the progress of patients receiving treatment for obesity, diabetes, and/or metabolic syndrome. The polynucleotide sequences may be used qualitative or quantitative assays, e.g. in Southern or Northern analysis, dot blot or other membrane-based technologies; in PCR technologies; or in dip stick, pin, ELISA or chip assays utilizing fluids or tissues from patient biopsies to detect altered gene expression.
  • the TGF BETA IG-H3 nucleotide sequences may be useful in assays that detect activation or induction of various metabolic diseases or dysfunctions.
  • the nucleotide sequences may be labeled by standard methods, and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. The presence of altered levels of nucleotide sequences encoding TGF BETA IG-H3 in the sample indicates the presence of the associated disease.
  • Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials or in monitoring the treatment of an individual patient.
  • a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence or a fragment thereof, which is specific for the nucleic acids encoding the proteins of the invention and homologous nucleic acids, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with those from an experiment where a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for disease.
  • Deviation between standard and subject values is used to establish the presence of disease. Once disease is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to evaluate whether the level of expression in the patient begins to approximate that, which is observed in the normal patient. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.
  • the presence of an unusual amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms.
  • a more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the metabolic diseases and disorders.
  • oligonucleotides designed from the sequences encoding TGF BETA IG-H3 may involve the use of PCR.
  • Such oligomers may be chemically synthesized, generated enzymatically or produced from a recombinant source. Oligomers will preferably consist of two nucleotide sequences, one with sense orientation (5prime.fwdarw.3prime) and another with antisense (3prime.rarw.5prime), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantification of closely related DNA or RNA sequences.
  • the nucleic acid sequences may also be used to generate hybridization probes, which are useful for mapping the naturally occurring genomic sequence.
  • the sequences may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques.
  • Such techniques include FISH, FACS or artificial chromosome constructions, such as yeast artificial chromosomes, bacterial artificial chromosomes, bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price, C. M. (1993) Blood Rev. 7: 127-134, and Trask, B. J. (1991 ) Trends Genet. 7: 149-154.
  • FISH as described in Verma et al.
  • the nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier or affected individuals. An analysis of polymorphisms, e.g. single nucleotide polymorphisms may be carried out. Further, in situ hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms or parts thereof, by physical mapping.
  • any sequences mapping to that area may represent associated or regulatory genes for further investigation.
  • the nucleotide sequences of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier or affected individuals.
  • the proteins of the invention in another embodiment, can be used for screening libraries of compounds in any of a variety of drug screening techniques.
  • effectors e.g. receptors, enzymes, proteins, ligands, or substrates that bind to, modulate or mimic the action of one or more of the TGF BETA IG-H3 proteins of the invention.
  • the protein or fragment thereof employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellulary.
  • the formation of binding complexes, between the TGF BETA IG-H3 proteins of the invention and the agent tested, may be measured. Agents could also, either directly or indirectly, influence the activity of the proteins of the invention.
  • agents may also interfere with posttranslational modifications of the protein, such as phosphorylation and dephosphorylation, farnesylation, palmitoylation, acetylation, alkylation, ubiquitination, proteolytic processing, subcellular localization and degradation.
  • agents could influence the dimerization or oligomerization of the proteins of the invention or, in a heterologous manner, of the proteins of the invention with other proteins, for example, but not exclusively, docking proteins, enzymes, receptors, or translation factors.
  • Agents could also act on the physical interaction of the proteins of this invention with other proteins, which are required for protein function, for example, but not exclusively, their downstream signaling.
  • binding of a fluorescently labeled peptide derived from the interacting protein to the TGF BETA IG-H3, or vice versa could be detected by a change in polarisation.
  • binding partners which can be either the full length proteins as well as one binding partner as the full length protein and the other just represented as a peptide are fluorescently labeled
  • binding could be detected by fluorescence energy transfer (FRET) from one fluorophore to the other.
  • FRET fluorescence energy transfer
  • TGF BETA IG-H3 proteins of the invention could be the basis for a cell-based screening assay, in which both proteins are fluorescently labeled and interaction of both proteins is detected by analysing cotranslocation of both proteins with a cellular imaging reader, as has been developed for example, but not exclusively, by Cellomics or EvotecOAI.
  • the two or more binding partners can be different proteins with one being TGF BETA IG-H3, or in case of dimerization and/or oligomerization TGF BETA IG-H3 itself.
  • agent as used herein describes any molecule, e.g. protein or pharmaceutical, with the capability of altering or mimicking the physiological function of one or more of the proteins of the invention.
  • Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 Daltons.
  • Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups.
  • the candidate agents often comprise carbocyclic or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups.
  • Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, nucleic acids and derivatives, structural analogs or combinations thereof.
  • Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides.
  • libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced.
  • natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries.
  • pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.
  • the screening assay is a binding assay
  • one or more of the molecules may be joined to a label, where the label can directly or indirectly provide a detectable signal.
  • Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564.
  • large numbers of different small test compounds e.g, aptamers, peptides, low-molecular weight compounds etc.
  • the test compounds are reacted with the proteins or fragments thereof, and washed. Bound proteins are then detected by methods well known in the art. Purified proteins can also be coated directly onto plates for use in the aforementioned drug screening techniques.
  • non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.
  • TGF BETA IG-H3 proteins e.g. antibodies
  • Such cell populations are useful in transplantation, for experimental evaluation, and as source of lineage and cell specific products, including mRNA species useful in identifying genes specifically expressed in these cells, and as target for the identification of factors of molecules that can affect them.
  • Cells expressing the protein of the invention or which have been treated with the protein of the invention are useful in transplantation to provide a recipient with pancreatic islet cells, including insulin producing beta cells; for drug screening; experimental models of islet differentiation and interaction with other cell types; in vitro screening assays to define growth and differentiation factors, and to additionally characterize genes involved in islet development and regulation; and the like.
  • the native cells may be used for these purposes, or they may be genetically modified to provide altered capabilities.
  • Cells from a regenerating pancreas, from embryonic foregut, stomach and duodenum, or other sources of pancreatic progenitor cells may be used as a starting population.
  • the progenitor cells may be obtained from any mammalian species, e.g. equine, bovine, porcine, canine, feline, rodent, e.g. mice, rats, hamster, primate, etc. particularly human.
  • the cells are transfected with a DNA construct, e.g. a viral or non-viral vector containing a reporter gene, e.g. the lacZ gene or the GFP gene, under regulatory control of a promoter of a gene involved in for example beta-cell differentiation, e.g. a promoter of a gene stimulation beta-cell differentiation, preferably a Pax4 promoter.
  • a promoter of a gene involved in for example beta-cell differentiation e.g. a promoter of a gene stimulation beta-cell differentiation, preferably a Pax4 promoter.
  • the transfected cells are divided into aliquots and each aliquot is contacted with a test substance, e.g., candidate 1 , candidate 2 and candidate 3.
  • the activity of the reporter gene corresponds to the capability of the test compound to induce beta-cell differentiation.
  • a medium throughput validation is carried out.
  • the test compound is added to stem cells being cultivated and the insulin production is determined.
  • an initial high throughput assay such as the cell based assay outlined above where for example a Pax4 promoter is used as marker for beta-cell regeneration
  • the activity of candidate molecules to induce beta-cell differentiation is tested in a validation assay comprising adding said compounds to the culture media of the embryoid bodies. Differentiation into insulin-producing cells is then evaluated, e.g. by comparison to wild type and/or Pax4 expressing ES cells to assess the effectiveness of a compound.
  • the nucleic acids encoding the TGF BETA IG-H3 proteins of the invention can be used to generate transgenic cell lines and animals. These transgenic non-human animals are useful in the study of the function and regulation of the proteins of the invention in vivo.
  • Transgenic animals particularly mammalian transgenic animals, can serve as a model system for the investigation of many developmental and cellular processes common to humans.
  • a variety of non-human models of metabolic disorders can be used to test modulators of TGF BETA IG-H3.
  • Misexpression for example, overexpression or partial or complete lack of expression
  • such assays use mouse models of insulin resistance and/or diabetes, such as mice carrying gene knockouts in the leptin pathway (for example, ob (leptin) or db (leptin receptor) mice), as described above.
  • these mice could be used to test whether administration of a candidate modulator alters for example lipid accumulation in the liver, in plasma, or adipose tissues using standard assays well known in the art, such as FPLC, colorimetric assays, blood glucose level tests, insulin tolerance tests and others.
  • Transgenic animals may be made through homologous recombination in embryonic stem cells, where the normal locus of the gene encoding TGF BETA IG-H3 is mutated.
  • a nucleic acid construct encoding the protein is injected into oocytes and is randomly integrated into the genome.
  • One may also express the genes of the invention or variants thereof in tissues where they are not normally expressed or at abnormal times of development.
  • variants of the genes of the invention like specific constructs expressing anti-sense molecules or expression of dominant negative mutations, which will block or alter the expression of the proteins of the invention may be randomly integrated into the genome.
  • a detectable marker such as lac Z or luciferase may be introduced into the locus of the genes of the invention, where upregulation of expression of the genes of the invention will result in an easily detectable change in phenotype.
  • Vectors for stable integration include plasmids, retroviruses and other animal viruses, yeast artificial chromosomes (YACs), and the like.
  • DNA constructs for homologous recombination will contain at least portions of the genes of the invention with the desired genetic modification, and will include regions of homology to the target locus. Conveniently, markers for positive and negative selection are included. DNA constructs for random integration do not need to contain regions of homology to mediate recombination.
  • DNA constructs for random integration will consist of the nucleic acids encoding the proteins of the invention, a regulatory element (promoter), an intron and a poly-adenylation signal.
  • a regulatory element promoter
  • Methods for generating cells having targeted gene modifications through homologous recombination are known in the field.
  • embryonic stem (ES) cells an ES cell line may be employed, or embryonic cells may be obtained freshly from a host, e.g. mouse, rat, guinea pig, etc. Such cells are grown on an appropriate fibroblast-feeder layer and are grown in the presence of leukemia inhibiting factor (LIF). ES or embryonic cells may be transfected and can then be used to produce transgenic animals.
  • LIF leukemia inhibiting factor
  • the ES cells are plated onto a feeder layer in an appropriate medium.
  • Cells containing the construct may be selected by employing a selection medium. After sufficient time for colonies to grow, they are picked and analyzed for the occurrence of homologous recombination. Colonies that are positive may then be used for embryo manipulation and morula aggregation. Briefly, morulae are obtained from 4 to 6 week old superovulated females, the Zona Pellucida is removed and the morulae are put into small depressions of a tissue culture dish. The ES cells are trypsinized, and the modified cells are placed into the depression closely to the morulae.
  • the transgenic animals may be any non-human mammal, such as laboratory animal, domestic animals, etc., for example, mouse, rat, guinea pig, sheep, cow, pig, and others.
  • the transgenic animals may be used in functional studies, drug screening, and other applications and are useful in the study of the function and regulation of the proteins of the invention in vivo.
  • the invention also relates to a kit comprising at least one of
  • TGF BETA IG-H3 protein or a fragment or an isoform thereof (b) TGF BETA IG-H3 protein or a fragment or an isoform thereof; (c) a vector comprising the nucleic acid of (a);
  • the kit may be used for diagnostic or therapeutic purposes or for screening applications as described above.
  • the kit may further contain user instructions.
  • Figure 1 shows the content of energy storage triglyceride (TG) of Drosophila Fasciclin 1 (Fas1 ; GadFly Accession Number CG6588) mutants. Shown is the change of triglyceride content of HD-EP(3)32580 and HD-EP(3)35618 flies caused by integration of the P-vectors into the annotated transcription unit ('HD-EP35618', column 2 and 'HD-EP32580', column 3) in comparison to controls containing all fly lines of the proprietary EP collection ('EP-control', column 1 ).
  • TG energy storage triglyceride
  • Fasciclin 1 Fes1 ; GadFly Accession Number CG6588
  • Figure 2 shows the molecular organization of the mutated Fasciclin 1 (Fas1 ; GadFly Accession Number CG6588) gene locus.
  • Figure 3 shows human TGF BETA IG-H3 nucleic acid and protein
  • Figure 3A shows the nucleic acid sequence encoding human TGF BETA IG-H3 protein (SEQ ID NO: 1 )
  • Figure 3B shows the amino acid sequence (one-letter code) of human TGF BETA IG-H3 protein (SEQ ID NO: 2).
  • FIG 4 shows the analysis of TGF BETA IG-H3 protein expression in mammalian tissues.
  • the relative RNA-expression is shown on the Y-axis, in Figure 2A to 2C the. tissues tested are given on the X-axis.
  • WAT refers to white adipose tissue
  • BAT refers to brown adipose tissue.
  • the X-axis represents the time axis.
  • 'dO' refers to day 0 (start of the experiment)
  • 'd2' - 'd10' refers to day 2 - day 10 of adipocyte differentiation).
  • Figure 4A shows the quantitative analysis of TGF BETA IG-H3 expression in mouse wild-type tissues.
  • Figure 4B shows the quantitative analysis of TGF BETA IG-H3 expression in wild-type mice (wt-mice), compared to genetically obese mice (ob/ob-mice) and to fasted mice (fasted-mice).
  • Figure 4C shows the quantitative analysis of TGF BETA IG-H3 expression in mice fed with a control diet compared to mice fed with a high fat diet.
  • Figure 5A shows the quantitative analysis of TGF BETA IG-H3 expression in human abdominal adipocyte cells, during the differentiation from preadipocytes to mature adipocytes.
  • Figure 5B shows the quantitative analysis of TGF BETA IG-H3 expression in human abdominal adipocyte cells, during the differentiation from preadipocytes to mature adipocytes.
  • Example 1 Measurement of triglyceride content
  • Mutant flies are obtained from a fly mutation stock collection.
  • the flies are grown under standard conditions known to those skilled in the art.
  • additional feedings with bakers yeast Sacharomyces cerevisiae
  • the average change of triglyceride content of Drosophila containing the EP-vectors as integration was investigated in comparison to control flies.
  • flies were incubated for 5 min at 90?C in an aqueous buffer using a waterbath, followed by hot extraction.
  • the triglyceride content of the flies extract was determined using Sigma Triglyceride (INT 336-10 or -20) assay by measuring changes in the optical density according to the manufacturer's protocol.
  • the protein content of the same extract was measured using BIO-RAD DC Protein Assay according to the manufacturer's protocol.
  • HD-EP(3)35618 and HD-EP(3)32580 homozygous flies show constantly a higher triglyceride content than the controls (column 2 in Figure 1 , 'HD-EP35618' and column 3 in Figure 1 , 'HD-EP32580'). Therefore, the loss of gene activity is responsible for changes in the metabolism of the energy storage triglycerides.
  • Example 2 Identification of Drosophila genes associated with metabolic regulation
  • HD-EP(3)35618 or HD-EP(3)32580 homozygous flies public databases like Berkeley Drosophila Genome Project (GadFly) were screened.
  • the chromosomal localization site of HD-EP(3)35618 and HD-EP(3)32580 vector integration is at gene locus 3R, 89D5-6.
  • Genomic DNA is represented as a dotted grey line in middle of the Figure that includes the integration sites of HD-EP(3)35618 and HD-EP(3)32580. Numbers represent the coodinates of the genomic DNA (starting at position 12378753 on chromosome 3R, ending at position 12403753 on chromosome 3R) .
  • the insertion site of the P-elements in Drosophila lines HD-EP(3)35618 or HD-EP(3)32580 are shown as triangles in the "P Elements + " and the "P Elements -" lines, respectively and are labeled.
  • a screen for secreted factors expressed in developing mouse pancreas was carried out according to methods known by those skilled in the art (see, for example Pera E.M. and De Robertis E.M., (2000) Mech Dev 96(2): 183-195) with several modifications.
  • a mouse embryonic stage 9.5-15 pancreatic bud library was prepared in pCMVSPORT-6 vector using SUPERSCRIPT Plasmid System from Invitrogen according to the manufacturer's instructions.
  • the non-amplified library was electroporated into MaxEff DH10B cells (Invitrogen).
  • Bacterial clones were picked with sterile toothpicks from agar plates and cultured in 96-deep-well microtiter plates in LB-ampicillin (see Sambrook et al., supra). Aliquots of 8 cultures were pooled, and plasmid DNA was isolated using the BioRobot_9600 apparatus according to the manufacturer's instructions (Qiagen; QIAprep(r) Turbo BioRobot Kit. Human 293 cell culture cells were cultured in 75 ml tissue culture flasks in DMEM and 10% fetal calf serum. At 90-99% confluence, the cells were splitted at 1 :3 ratio and plated onto poly-D-lysine (Sigma) coated 96-well plates.
  • Cells were transfected with 100-500 ng plasmid using lipofectamine 2000 (Invitrogen). After 6 hours, the medium was exchanged for fresh complete growth medium. 24 hours after transfection, the cells were washed twice with DMEM without cysteine and methionine (Invitrogen), supplemented with 1 % dialysed Bovine serum (Sigma) with 50 ⁇ g per ml heparin (Sigma) and glutamine. The cells were labeled radioactively ('S35 Met-label', from Hartmann Analytic GmbH).
  • polynucleotide comprising the nucleotide sequence as shown in GenBank Accession number relates to the expressible gene of the nucleotide sequences deposited under the corresponding GenBank Accession number.
  • GenBank Accession number relates to NCBI GenBank database entries (Ref.: Benson et al., Nucleic Acids Res. 28 (2000) 1 5-1 8).
  • Drosphila fasciclin 1 and to mouse IMHO were identified using the publicly available program BLASTP 2.2.3 of the non-redundant protein data base of the National Center for Biotechnology Information (NCBI) (see, Altschul et al., 1 997, Nucleic Acids Res. 25:3389-3402).
  • a human homolog of Drosphila fas 1 and mouse IMHO is Homo sapiens transforming growth factor, beta induced, 68kD, corneal dystrophy, kerato-epithelin, GenBank Accession Number NM_000358 (SEQ ID NO: 1 , see Figure 3) and GenBank Accession Number NP 000349.1 (683 amino acid protein; SEQ ID NO: 2, see Figure 3).
  • Another human homolog of Drosphila fascilin 1 and mouse IMHO is osteoblast specific factor 2 (fasciclin 1 -like, periostin, GenBank Accession Number NP 006466.1 ).
  • mice strains preferably mice strains C57BI/6J, C57BI/6 ob/ob and C57BI/KS db/db which are standard model systems in obesity and diabetes research
  • Harlan Winkelmann 33178 Borchen, Germany
  • constant temperature preferably 22°C
  • 40 per cent humidity preferably 14 / 10 hours.
  • the mice were fed a standard chow (for example, from ssniff Spezialitaten GmbH, order number ssniff M-Z V1 126-000).
  • mammalian fibroblast (3T3-L1 ) cells e.g., Green & Kehinde, Cell 1 : 1 13-1 16, 1974
  • 3T3-L1 cells were maintained as fibroblasts and differentiated into adipocytes as described in the prior art (e.g., Qiu. et al., J. Biol. Chem.
  • dO dO cells were transferred to serum-free (SF) medium, containing DMEM/HamF12 (3:1 ; Invitrogen), fetuin (300 //g/ml; Sigma, Kunststoff, Germany), transferrin (2 /g/ml; Sigma), pantothenate (17 ⁇ M; Sigma), biotin (1 ⁇ M; Sigma), and EGF (O. ⁇ nM; Hoffmann-La Roche, Basel, Switzerland).
  • Differentiation was induced by adding dexamethasone (DEX; 1 ⁇ M; Sigma), 3-methyl-isobutyl-1 -methylxanthine (MIX; 0.5mM; Sigma), and bovine insulin (5/yg/ml; Invitrogen).
  • DEX dexamethasone
  • MIX 3-methyl-isobutyl-1 -methylxanthine
  • bovine insulin 5/yg/ml; Invitrogen).
  • d4 Four days after confluence (d4), cells were kept in SF medium, containing bovine insulin (5 //g/ml) until differentiation was completed. At various time points of the differentiation procedure, beginning with day 0 (day of confluence) and day 2 (hormone addition; for example, dexamethasone and 3-isobutyl-1 -methylxanthine), up to 10 days of differentiation, suitable aliquots of cells were taken every two days.
  • Trizol Reagent for example, from Invitrogen, Düsseldorf, Germany
  • RNeasy Kit for example, from Qiagen, Germany
  • mice TGF BETA IG-H3 reverse primer (Seq ID NO:3) 5'-CAGTCATCAACTTCATGACCCAAG -3'; Mouse TGF BETA IG-H3 reverse primer (Seq ID NO:4) 5'-CTGTTACACGTGGATCCTTTGC-3'; Mouse TGF BETA IG-H3 Taqman probe (Seq ID NO:5) (5/6-FAM)-TCCACTGTGACACCAAGATGAAGGACTCA-(5/6-TAMRA) .
  • Example 6 Analysis of the differential expression of transcripts of the proteins of the invention in human tissues (FIGURE 5)
  • RNA preparation from human primary adipose tissues was done as described in EXAMPLE 5.
  • the hybridization and scanning was performed as described in the manufactures manual (see Affymetrix Technical Manual, 2002, obtained from Affymetrix, Santa Clara, USA).
  • the expression analysis (using Affymetrix GeneChips) of the TGF BETA IG-H3 gene using primary human abdominal adipocycte differentiation clearly shows differential expression of human TGF BETA IG-H3 in adipocytes.
  • Two independent experiments were done. Both experiments show that the TGF BETA IG-H3 transcripts are the most abundance at day 0 compared to day 12 during differentiation.
  • the TGF BETA IG-H3 protein has to be significantly decreased in order for the preadipocyctes to differentiate into mature adipocycte.
  • the TGF BETA IG-H3 protein in preadipocyctes has the potential to inhibit adipose differentiation. Therefore, the TGF BETA IG-H3 protein might play an essential role in the regulation of human metabolism, in particular in the regulation of adipogenesis and thus it might be an essential role in obesity, diabetes, and/or metabolic syndrome.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouvelles utilisations de protéines sécrétées intervenant dans la régulation du métabolisme des triglycérides, qui permettent de diagnostiquer, étudier, prévenir et traiter des pathologies et troubles métaboliques.
PCT/EP2003/008244 2002-07-26 2003-07-25 Utilisation de tgf beta ig-h3 dans la prevention et le traitement de l'obesite, du diabete et/ou du syndrome metabolique Ceased WO2004012758A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003251646A AU2003251646A1 (en) 2002-07-26 2003-07-25 Use of tgf beta ig-h3 for preventing and treating obesity, diabetes and/or metabolic syndrome

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP02016773.0 2002-07-26
EP02016773 2002-07-26
EP03007831 2003-04-04
EP03007831.5 2003-04-04

Publications (1)

Publication Number Publication Date
WO2004012758A1 true WO2004012758A1 (fr) 2004-02-12

Family

ID=31497084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008244 Ceased WO2004012758A1 (fr) 2002-07-26 2003-07-25 Utilisation de tgf beta ig-h3 dans la prevention et le traitement de l'obesite, du diabete et/ou du syndrome metabolique

Country Status (2)

Country Link
AU (1) AU2003251646A1 (fr)
WO (1) WO2004012758A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2463657A1 (fr) * 2010-12-13 2012-06-13 Université de Liège Biomarqueurs, utilisation des biomarqueurs et procédé d'identification des biomarqueurs
US11622946B2 (en) * 2016-04-11 2023-04-11 Gat Therapeutics, S.L. Uses of a carotenoid in the treatment or prevention of stress induced conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444164A (en) * 1992-02-05 1995-08-22 Bristol-Myers Squibb Company TGF-β induced gene
US5714588A (en) * 1994-07-01 1998-02-03 Advanced Tissue Sciences Enhancement of cellular attachment using H3 protein
WO2001087928A1 (fr) * 2000-05-13 2001-11-22 Regen Biotech, Inc. Peptides et derives presentant une activite de fixation, de propagation et d'ablation cellulaire

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444164A (en) * 1992-02-05 1995-08-22 Bristol-Myers Squibb Company TGF-β induced gene
US5714588A (en) * 1994-07-01 1998-02-03 Advanced Tissue Sciences Enhancement of cellular attachment using H3 protein
WO2001087928A1 (fr) * 2000-05-13 2001-11-22 Regen Biotech, Inc. Peptides et derives presentant une activite de fixation, de propagation et d'ablation cellulaire

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ABRASS CHRISTINE K ET AL: "Expression of betaig-h3 by rat mesangial cells (MC) and accumulation in the mesangium in humans with diabetes mellitus", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 12, no. Program and Abstract Issue, September 2001 (2001-09-01), ASN (American Society of Nephrology)/ISN (International Society of Nephrology) World Congress of Nep;San Francisco, CA, USA; October 10-17, 2001, pages 699A, XP009018894, ISSN: 1046-6673 *
AHDJOUDJ S ET AL: "Transforming growth factor-beta prevents and reverses bone marrow adipogenesis induced by skeletal unloading in rats", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 16, no. Suppl. 1, September 2001 (2001-09-01), Twenty-Third Annual Meeting of the American Society for Bone and Mineral Research;Phoenix, Arizona, USA; October 12-16, 2001, pages S143, XP009019017, ISSN: 0884-0431 *
COOK T ET AL: "TIEG proteins join the Smads as TGF-beta-regulated transcription factors that control pancreatic cell growth.", AMERICAN JOURNAL OF PHYSIOLOGY. GASTROINTESTINAL AND LIVER PHYSIOLOGY. UNITED STATES APR 2000, vol. 278, no. 4, April 2000 (2000-04-01), pages G513 - G521, XP009018890, ISSN: 0193-1857 *
GENG MICHAEL M ET AL: "Use of representational difference analysis to study the effect of TGFB on the expression profile of a pancreatic cancer cell line", GENES, CHROMOSOMES & CANCER, XX, XX, vol. 26, no. 1, 1999, pages 70 - 79, XP002166292 *
HA SUNG-WOO ET AL: "TGF-beta-induced protein betaig-h3 is upregulated by high glucose in vascular smooth muscle cells.", JOURNAL OF CELLULAR BIOCHEMISTRY. UNITED STATES 1 MAR 2003, vol. 88, no. 4, 1 March 2003 (2003-03-01), pages 774 - 782, XP009018898, ISSN: 0730-2312 *
MENKE A ET AL: "Transforming growth factor-beta-induced upregulation of transforming growth factor-beta receptor expression in pancreatic regeneration.", BIOCHIMICA ET BIOPHYSICA ACTA. NETHERLANDS 8 MAR 1999, vol. 1449, no. 2, 8 March 1999 (1999-03-08), pages 178 - 185, XP004277960, ISSN: 0006-3002 *
SCHNEIDER DOMINIK ET AL: "Induction and expression of betaig-h3 in pancreatic cancer cells.", BIOCHIMICA ET BIOPHYSICA ACTA. NETHERLANDS 9 OCT 2002, vol. 1588, no. 1, 9 October 2002 (2002-10-09), pages 1 - 6, XP004388038, ISSN: 0006-3002 *
SKONIER J ET AL: "BETAIG-H3: A TRANSFORMING GROWTH FACTOR-BETA-RESPONSIVE GENE ENCODING A SECRETED PROTEIN THAT INHIBITS CELL ATTACHMENT IN VITRO AND SUPPRESSES THE GROWTH OF CHO CELLS IN NUDE MICE", DNA AND CELL BIOLOGY, NEW YORK, NY, US, vol. 13, no. 6, 1994, pages 571 - 584, XP002914800, ISSN: 1044-5498 *
SKONIER J ET AL: "CDNA CLONING AND SEQUENCE ANALYSIS OF BETAIG-H3, A NOVEL GENE INDUCED IN A HUMAN ADENOCARCINOMA CELL LINE AFTER TREATMENT WITH TRANSFORMING GROWTH FACTOR-BETA", DNA AND CELL BIOLOGY, NEW YORK, NY, US, vol. 11, no. 7, September 1992 (1992-09-01), pages 511 - 522, XP008011176, ISSN: 1044-5498 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2463657A1 (fr) * 2010-12-13 2012-06-13 Université de Liège Biomarqueurs, utilisation des biomarqueurs et procédé d'identification des biomarqueurs
US11622946B2 (en) * 2016-04-11 2023-04-11 Gat Therapeutics, S.L. Uses of a carotenoid in the treatment or prevention of stress induced conditions

Also Published As

Publication number Publication date
AU2003251646A1 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
US20090298771A1 (en) Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
EP1605965B1 (fr) Utilisation de proteines associees a la saposine pour la prevention et le traitement de l'obesite, du diabete et/ou du syndrome metabolique
EP2289908B1 (fr) Utilisation de produits des protéines DG177 sécretées pour la prévention et le traitement de maladies du pancreas et/ou de l'obésité et/ou du syndrome métabolique
WO2004012758A1 (fr) Utilisation de tgf beta ig-h3 dans la prevention et le traitement de l'obesite, du diabete et/ou du syndrome metabolique
US20060259988A1 (en) Use of dg931 protein for treating diabetes, obesity and metabolic syndrome
EP1644027B1 (fr) Utilisation de pleitrophine pour prevenir et traiter des maladies pancreatiques et / ou l'obesite et / ou le syndrome metabolique
US20060234930A1 (en) Use of dg008,dg065,dg210 or dg239 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
EP2135618B1 (fr) SF6 pour son utilisation dans le traitement du diabète et / ou de l'obésité, méthodes de criblage pour modulateurs et Kit
US20080107639A1 (en) Use of a Dg147 Protein Product for Preventing and Treating Metabolic Disorders
WO2004020465A2 (fr) Proteines intervenant dans la regulation de l'homeostasie energetique
US20060168667A1 (en) Minibrain homologous proteins involved in the regulation of energy homeostasis
EP1706134A2 (fr) Utilisation de produits proteiques permettant de prevenir et de traiter les maladies du pancreas et/ou l'obesite et/ou le syndrome metabolique
US20050272915A1 (en) Skrp, astray, string, vacm associated with metabolic control
WO2004047855A2 (fr) Proteines impliquees dans la regulation de l'homeostasie de l'energie
EP1546341A1 (fr) Acides nucleiques et proteines homologues mipp1 impliques dans la regulation de l'homeostasie energetique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP